Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Open accessAbstract
AIMS: Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisin/kexin type 9 production, in primary prevention patients with elevated LDL-C despite statins. METHODS AND RESULTS: This pre-specified analysis of the placebo-controlled, randomized ORION-11 trial included 203 individuals at risk of, but without prior, cardiovascular events and LDL-C ≥2.6 mmol/L, despite maximally tolerated statins. Inclisiran 284 mg or placebo was administered on Days 1, 90, and thereafter every 6 months up to 540 days. Co-primary endpoints were percentage LDL-C change from baseline to Day 510 and time-adjusted change from baseline after Day 90 and up to Day 540. Key secondary endpoints included percentage and absolute changes in atherogenic lipoproteins. Safety was assessed over 540 days. The mean baseline (SD) LDL-C was 3.6 (1.5) mmol/L. At Day 510, the placebo-corrected LDL-C change with inclisiran was -43.7% [95% confidence interval (CI): -52.8 to -34.6] with a corresponding time-adjusted change of -41.0% (95% CI: -47.8 to -34.2); (P < 0.0001). The placebo-corrected absolute change in LDL-C at Day 510 with inclisiran was -1.5 mmol/L (95% CI: -1.8 to -1.2), with a respective time-adjusted change of -1.3 mmol/L (95% CI: -1.6 to -1.1). Inclisiran significantly lowered non-HDL cholesterol and apolipoprotein B (apoB) at Day 510 vs. placebo (P < 0.0001 for both), with a greater likelihood of attaining lipoprotein and apoB goals, and was well-tolerated except for mainly mild, treatment-emergent adverse events at the injection site. CONCLUSION: Inclisiran was generally well-tolerated in primary prevention patients with elevated LDL-C, who derived significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The lipid trials demonstrate positive effects on apolipoprotein B (apoB) levels together with non-HDL cholesterol and lipoprotein(a) as well as LDL-C reduction.
“The lipid trials demonstrate positive effects on apolipoprotein B (apoB) levels together with non-HDL cholesterol and lipoprotein(a) as well as LDL-C reduction [45, 59].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 19 · Cited by 116
Research works printed but not linked: 14
- [1]Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111– 188. 10.1093/eurheartj/ehz455 31504418 · DOI · Paper page
- [3]Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306: 2120– 2127. 10.1001/jama.2011.1654 22089719 PMC4494683 · DOI
- [4]Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J 2018; 39: 3766– 3776. 10.1093/eurheartj/ehy554 30239671 · DOI
- [5]Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 2020; 76: 2982– 3021. 10.1016/j.jacc.2020.11.010 33309175 PMC7755038 · DOI · Paper page
- [6]Khvorova A. Oligonucleotide therapeutics — a new class of cholesterol-lowering drugs. N Engl J Med 2017; 376: 4– 7. 10.1056/NEJMp1614154 28052224 · DOI
- [9]Wright RS, Ray KK, Raal FJ, Kallend D, Jaros M, Koenig W, et al Patient-Level pooled analysis of inclisiran efficacy and safety in the ORION phase III program. J Am Coll Cardiol 2021; 77: 1182– 1193. 10.1016/j.jacc.2020.12.058 33663735 · DOI · Paper page
- [11]Pender A, Lloyd-Jones DM, Stone NJ, Greenland P. Refining statin prescribing in lower-risk individuals: informing risk/benefit decisions. J Am Coll Cardiol 2016; 68: 1690– 1697. 10.1016/j.jacc.2016.07.753 27712783 · DOI
- [12]Byrne P, Cullinan J, Murphy C, Smith SM. Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease. BMJ Open 2018; 8: e018524. 10.1136/bmjopen-2017-018524 PMC5829660 29439070 · DOI
- [13]Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, et al Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Netw Open 2018; 1: e185554. 10.1001/jamanetworkopen.2018.5554 30646277 PMC6324347 · DOI
- [14]Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64: 485– 494. 10.1016/j.jacc.2014.02.615 25082583 PMC4443441 · DOI · Paper page
- [15]Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open 2019; 9: e023085. 10.1136/bmjopen-2018-023085 PMC6500096 31015265 · DOI
- [16]Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 2017; 38: 2459– 2472. 10.1093/eurheartj/ehx144 28444290 PMC5837225 · DOI · Paper page
- [17]Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration. Eur Heart J 2018; 39: 2540– 2545. 10.1093/eurheartj/ehx450 29020411 PMC6047439 · DOI · Paper page
- [18]Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al EU-Wide Cross-Sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021; 28: 1279– 1289. 10.1093/eurjpc/zwaa047 33580789 · DOI · Paper page
- Authors
- Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., & ORION-11 Investigators
- Affiliations
- Imperial College London (GB)
- LIB Therapeutics LLC (United States) (US)
- St. Michael's Hospital (CA)
- University of the Witwatersrand (ZA)
- German Heart Centre, Technical University Munich, DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance , Munich , Germany
- Summit Analytical , Denver, CO , USA
- University of Colorado Anschutz (US)
- German Centre for Cardiovascular Research (DE)
- Novartis Pharma AG , Basel , Switzerland
- Mayo Clinic (US)
- Corresponding author
- Ray, Kausik K
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-04
- Volume
- 43
- Issue
- 48
- Pages
- 5047-5057
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC9769955
- OpenAlex
- W4308178887
- Cited by
- 116
- References
- 19
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 39 · 2023: 24 · 2022: 2
- FWCI
- 21.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Novartis Pharma AG
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- inclisiran, PCSK9 inhibition, primary prevention, atherosclerotic cardiovascular disease, LDL cholesterol lowering, statin-resistant hypercholesterolemia, non-HDL cholesterol, apolipoprotein B, atherogenic lipoproteins, lipid-lowering therapy, safety and tolerability, injection site reactions
- MeSH terms
- Proprotein Convertase 9, Anticholesteremic Agents, Apolipoproteins B, Cholesterol, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
